XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2
Revenue from Contracts with Customers
 6 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers
3. Revenue from Contracts with Customers
The following table summarizes revenue by revenue source as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
Major Products/Service Lines (in thousands)2024202320242023
    Product revenue, net(1)
$392,756 $314,084 $762,069 $606,340 
    License and royalty revenues1,335 7,616 1,997 16,144 
Total revenues$394,091 $321,700 $764,066 $622,484 
________________________________
(1)The Company’s product revenue includes PYLARIFY and DEFINITY among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products.
The Company classifies its revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Radiopharmaceutical Oncology includes PYLARIFY and AZEDRA. In the first quarter of 2024, the Company discontinued the production of AZEDRA. Precision Diagnostics includes DEFINITY, TechneLite and other diagnostic imaging products. Strategic Partnerships and Other Revenue includes strategic partnerships and other arrangements related to other products of the Company. On August 2, 2023, the Company sold its rights to the RELISTOR net sales royalty asset (the “RELISTOR royalty asset”) under its license agreement with Bausch Health Companies, Inc. (“Bausch”); the Company retained the rights to future sales-based milestone payments.
Revenue by product category on a net basis is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
(in thousands)2024202320242023
   PYLARIFY$273,255 $210,522 $532,125 $405,992 
   Other radiopharmaceutical oncology— 818 384 1,535 
Total radiopharmaceutical oncology273,255 211,340 532,509 407,527 
   DEFINITY78,100 70,529 154,664 139,353 
   TechneLite28,186 21,594 49,900 42,580 
   Other precision diagnostics5,825 5,454 11,757 11,261 
Total precision diagnostics112,111 97,577 216,321 193,194 
Strategic partnerships and other revenue8,725 12,783 15,236 21,763 
Total revenues$394,091 $321,700 $764,066 $622,484 
The Company is required to allocate a portion of its revenue received from commercial contracts to future reporting periods to the extent the Company had performance obligations that extended beyond one year. However, the Company’s performance
obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.